Twelve immunotherapy drugs that could cure cancers

Area of Science:

• Immunology
• Oncology
• Cancer Therapy

Background:

• Immune T cells play a crucial role in cancer cell elimination.
• Cancer vaccines aim to boost T-cell numbers, but face biological limitations.
• Existing biological restrictions hinder the efficacy of current cancer vaccines.

Purpose of the Study:

• To review immunotherapeutic agents that bypass biological restrictions on T-cell activation.
• To highlight the potential of combination regimens for cancer treatment.
• To address the challenge of agent availability in translational cancer research.

Main Methods:

• Focus on 12 National Cancer Institute-vetted agents with proven T-cell augmentation capabilities.
• Analysis of immunotherapeutic agents including dendritic cell activators, vaccine adjuvants, T-cell stimulators, immune checkpoint inhibitors, and agents targeting suppressive factors.
• Review of strategies to circumvent biological limitations on T-cell responses.

Main Results:

• Several classes of immunotherapeutic agents can circumvent biological restrictions on T-cell responses.
• Individual agents have limited efficacy, but combinations demonstrate high potential.
• A significant challenge is the limited broad availability of these promising agents.

Conclusions:

• Combination immunotherapy regimens, guided by biological principles, are likely to significantly impact cancer therapy.
• The development of innovative combination cancer therapy regimens hinges on the future availability of these agents.
• Translational research efforts are crucial for advancing combination cancer immunotherapy.